Dey N - Search Results

1

Bevacizumab confers additional advantage to the combination of trastuzumab plus pertuzumab in trastuzumab‑refractory breast cancer model.

Sun Y, Dey N, Brammer M, De P, Leyland-Jones B. Sun Y, et al. Among authors: dey n. Cancer Chemother Pharmacol. 2013 Oct;72(4):733-45. doi: 10.1007/s00280-013-2233-7. Cancer Chemother Pharmacol. 2013. PMID: 23959459

2

CSK negatively regulates nerve growth factor induced neural differentiation and augments AKT kinase activity.

Dey N, Howell BW, De PK, Durden DL. Dey N, et al. Exp Cell Res. 2005 Jul 1;307(1):1-14. doi: 10.1016/j.yexcr.2005.02.029. Exp Cell Res. 2005. PMID: 15890337

3

CSK controls retinoic acid receptor (RAR) signaling: a RAR-c-SRC signaling axis is required for neuritogenic differentiation.

Dey N, De PK, Wang M, Zhang H, Dobrota EA, Robertson KA, Durden DL. Dey N, et al. Mol Cell Biol. 2007 Jun;27(11):4179-97. doi: 10.1128/MCB.01352-06. Epub 2007 Feb 26. Mol Cell Biol. 2007. PMID: 17325034 Free PMC article.

4

A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.

Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Kundra V, Shu HK, Peng Q, Durden DL. Garlich JR, et al. Among authors: dey n. Cancer Res. 2008 Jan 1;68(1):206-15. doi: 10.1158/0008-5472.CAN-07-0669. Cancer Res. 2008. PMID: 18172313

5

The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration.

Dey N, Crosswell HE, De P, Parsons R, Peng Q, Su JD, Durden DL. Dey N, et al. Cancer Res. 2008 Mar 15;68(6):1862-71. doi: 10.1158/0008-5472.CAN-07-1182. Cancer Res. 2008. PMID: 18339867

6

Of mice and men: the evolution of animal welfare guidelines for cancer research.

Dey N, De P, Smith BR, Leyland-Jones B. Dey N, et al. Br J Cancer. 2010 May 25;102(11):1553-4. doi: 10.1038/sj.bjc.6605692. Br J Cancer. 2010. PMID: 20502459 Free PMC article. No abstract available.

7

Targeting basal-like breast cancers.

Dey N, Smith BR, Leyland-Jones B. Dey N, et al. Curr Drug Targets. 2012 Nov;13(12):1510-24. doi: 10.2174/138945012803530116. Curr Drug Targets. 2012. PMID: 22974394 Review.

8

Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hope.

De P, Miskimins K, Dey N, Leyland-Jones B. De P, et al. Among authors: dey n. Cancer Treat Rev. 2013 Aug;39(5):403-12. doi: 10.1016/j.ctrv.2012.12.002. Epub 2013 Jan 23. Cancer Treat Rev. 2013. PMID: 23352077 Review.

9

An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.

De P, Dey N, Terakedis B, Bergsagel PL, Li ZH, Mahadevan D, Garlich JR, Trudel S, Makale MT, Durden DL. De P, et al. Among authors: dey n. Cancer Chemother Pharmacol. 2013 Apr;71(4):867-81. doi: 10.1007/s00280-013-2078-0. Epub 2013 Jan 25. Cancer Chemother Pharmacol. 2013. PMID: 23355037 Free PMC article. Clinical Trial.

10

Dissecting GRB7-mediated signals for proliferation and migration in HER2 overexpressing breast tumor cells: GTP-ase rules.

Pradip D, Bouzyk M, Dey N, Leyland-Jones B. Pradip D, et al. Among authors: dey n. Am J Cancer Res. 2013 Apr 3;3(2):173-95. Print 2013. Am J Cancer Res. 2013. PMID: 23593540 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

545 results

Search Page

Filters